News 2023-06-23
Porton Pharma Solutions Welcomes Alexandra Pichard Nielsen, VP of Business Development, at BOS Basel 2023, Driving Innovation and Growth in the Pharmaceutical Industry
We’re honored to have Alexandra Pichard Nielsen, Vice President for Business Development at Porton Pharma Solutions Ltd., join us at BOS Basel 2023!
We are excited to witness Alexandra’s expertise and leadership in action as she explores new opportunities, fosters partnerships, and drives business growth for Porton Pharma.
Stay tuned for insightful updates on how Alexandra is spearheading our company’s expansion and shaping the future of the pharmaceutical industry.
Drop by our booth at Stand 17 if you want to catch up with Alexandra!
If you would like to preschedule a meeting, https://lnkd.in/eFzuWJBN
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
